We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Lupin Fires Back At Novartis In Lotrel Patent Spat

Law360 (November 5, 2007, 12:00 AM EST) -- Indian generics giant Lupin Ltd. filed counterclaims Monday in a suit over Lotrel, saying Novartis Corp. deceived the U.S. Patent and Trademark Office into issuing the patent to the billion-dollar hypertension drug.

According to the counterclaims Lupin filed in the Maryland district court suit, the patent covering the drug — U.S. Patent Number 6,162,802, which isn't set to expire until Dec. 19 — is invalid, but even if the court found otherwise, Lupin's own filing last year of an Abbreviated New Drug Application for the formulation...
To view the full article, register now.